Jonathan Lim is a physician-turned-life-sciences entrepreneur, investor, and CEO. He currently serves as the chairman and CEO of Ignyta, a precision oncology company pursuing an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. He also is the founder and managing partner of City Hill Ventures, a boutique life sciences investment fund. In March 2011, Dr. Lim co-founded and most recently served as Chairman and CEO of Eclipse Therapeutics, a Biogen Idec spinout. Eclipse was sold to Bionomics in 2012, and Lim now serves as on the Bionomics board. From May 2003 to December 2010, Dr. Lim was President, CEO, and a director of Halozyme Therapeutics, where he led the company’s growth from a privately held startup with 5 employees to a publicly traded company with 140 employees. Under his leadership, Halozyme became a public company, raised $300 million through financings and corporate partnerships, achieved two U.S. FDA approvals (one drug and one device), and built a deep pipeline of late-stage clinical drug candidates. He also was a management consultant with McKinsey & Co., an NIH postdoctoral fellow at Harvard University, and a general surgery resident at New York Hospital-Cornell. He holds B.S. and M.S. degrees from Stanford University, an M.D. from McGill University, and an M.P.H. from Harvard.